The team from the Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard, described the AI-guided screening of more than 800,000 compounds to reveal three drug candidates with comparable efficacy and superior medicinal chemistry properties than those currently under investigation.